Trading Statement
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Trading Update May 2021
DXS International plc ("DXS", the "Company"), the AQSE quoted
clinical decision support developer and supplier of clinical
decision support systems, is pleased to provide shareholders with
the following trading update.
For the twelve months ending April 2021, we are pleased to
announce that we have been able to achieve a similar profit to the
year ending 2020 with turnover marginally improved for the same
period. This was due to a slight increase in existing sales from
both the NHS and the Pharmaceutical industry and initial revenue
for the Hypertension program. Last financial year to 30 April 2020,
turnover was £3.28m and net profit was £429k.
Although launching our new solutions as originally intended has
been severely hampered due to the COVID pandemic occupying GP’s
focus, we have managed to continue with our pilots, albeit at a
slower pace than originally envisaged. As Covid related pressure on
GPs subsides we anticipate that we will be able to progress pilots
at a more normal pace.
The feedback obtained so far from the pilots has been excellent
with positives being highlighted and constructive criticism
enabling our teams to continue with fixes and enhancements.
Our process of applying for NHS GPIT Futures accreditation is
complete with all standards having been approved and we anticipate
formal accreditation being awarded imminently. This means that
Clinical Commissioning Groups (CCG’s) will be able to procure our
ExpertCare hypertension solution via a central NHS fund.
Regarding our international activities, we were sadly not
selected for phase II of the European Union’s Horizon Research and
Development programme. Although receiving much positive feedback
for the quality of our submission, the programme has decided to
take forward participants based in the EU requiring less EU
investment. However, we have benefitted hugely from being selected
for phase I which provided grant funding to develop our
understanding of the challenges across Europe for dealing with
Hypertension. This has enabled us to create a detailed blueprint
for adapting our Hypertension solution to meet these needs and
address new markets.
David Immelman, Chief Executive of DXS said:
“While there are early signs of the healthcare market beginning
to normalise, GPs and Primary Care staff remain pressured,
particularly while facing significant backlogs built up during the
past 18 months. This however has presented an opportunity which is
evident by the keen interest being shown in our CompleteCare cancer
toolkit which can potentially assist practices expedite cancer
treatment backlogs. Although frustrated by delays, our sales and
marketing team remain focused and we continue to persevere with our
sales and marketing efforts both in the UK and abroad.”
The Directors of DXS International plc accept responsibility for
this announcement
Enquiries:
David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
https://www.dxs-systems.co.uk |
|
Corporate
Advisor |
|
City &
Merchant David Papworth |
020 7101 7676 |
Corporate
Broker |
|
Hybridan LLPClaire Louise
Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jul 2023 to Jul 2024